Stay updated with breaking news from Codexis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stock analysts at Cantor Fitzgerald assumed coverage on shares of Codexis (NASDAQ:CDXS – Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $11.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 225.44% from the stock’s […]
Item 1.01. Entry into a Material Definitive Agreement. ...
REDWOOD CITY, Calif., Dec. 27, 2023 -- Codexis, Inc. , a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally...
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).
(RTTNews) - Enzyme engineering company Codexis, Inc. (CDXS) announced Wednesday it has entered into a purchase agreement with Nestle Health Scienc...